Pharmacokinetics, efficacy, and safety of a novel aripiprazole microsphere-based long-acting injectable formulation for schizophrenia: A multicenter, randomized controlled trial

TL;DR

A new long-acting injectable aripiprazole formulation (MS350) was tested and found to be as effective as the current version but with more stable levels in the blood and fewer side effects.

Contribution

MS350, a novel microsphere-based formulation of aripiprazole, offers improved pharmacokinetics and safety compared to existing formulations.

Findings

MS350 is bioequivalent to the microcrystalline formulation of aripiprazole.

MS350 provides more stable plasma levels over time.

MS350 demonstrates a better safety profile with fewer adverse events.

Abstract

Image 1

•A microsphere-based formulation of aripiprazole (MS350) was investigated.•MS350 was bioequivalent to microcrystalline formulation with more stable plasma levels.•MS350 had fewer adverse events, demonstrating a better safety profile.

A microsphere-based formulation of aripiprazole (MS350) was investigated.

MS350 was bioequivalent to microcrystalline formulation with more stable plasma levels.

MS350 had fewer adverse events, demonstrating a better safety profile.

Figures